BinaxNow Influenza A & B

Schnelltest für Influenza A/B

Manufacturer: ABBOTT

Die BinaxNOW Influenza A & B Card ist ein professioneller Influenza Schnelltest für den qualitativen Nachweis von Influenza-A- und Influenza-B-Antigenen. Der Test eignet sich für den Einsatz in Arztpraxen, Notaufnahmen und anderen Point-of-Care-Umgebungen mit Bedarf an schneller Differenzialdiagnostik. Ergebnisse liegen laut Hersteller innerhalb von 15 Minuten vor. Dieses Produkt gehört zur Kategorie Schnelltests für die professionelle Point-of-Care-Diagnostik.

Non-binding quote request

Quick response

No additional costs

Description

Die BinaxNOW Influenza A & B Card von Abbott ist ein immunchromatographischer In-vitro-Schnelltest zum qualitativen Nachweis von Influenza-A- und Influenza-B-Nukleoprotein-Antigenen. Der Test kann mit Nasopharyngeal-Abstrichen, Nasenabstrichen sowie Nasenspül- oder Aspiratproben verwendet werden.

Laut Hersteller ermöglicht der Test eine schnelle Unterstützung der Differenzialdiagnostik bei Verdacht auf Influenza-Infektionen. Die visuelle Auswertung ist einfach ablesbar und Ergebnisse stehen innerhalb von etwa 15 Minuten zur Verfügung. Integrierte Kontrollen unterstützen die Testdurchführung im klinischen Alltag. Der Schnelltest eignet sich insbesondere für Einrichtungen, die eine zeitnahe Entscheidungsunterstützung im Point-of-Care-Setting benötigen.

Parameter overview

Influenza A

Influenza B

Influenza A

Influenza B

It is possible that certain calculated parameters are not specified.

Tests (1)

BinaxNOW Influenza A & B

Parameter:

Influenza AInfluenza B

Probentyp:

AbstrichAtemwegsproben

Zeit bis zum Ergebnis:900 s

BinaxNOW Influenza A & B

Parameter:

Influenza AInfluenza B

Probentyp:

AbstrichAtemwegsproben

Zeit bis zum Ergebnis:900 s

Studies & Product Documents

Evaluation of high-throughput digital lateral flow immunoassays for the detection of influenza A/B viruses from clinical swab samples (Yoo et al., 2020)

The study compared the ID NOW (a rapid NAAT) with three digital LFIAs: BD Veritor Plus, STANDARD F, and ichroma TRIAS. While ID NOW demonstrated superior sensitivity, the digital LFIAs - particularly the ichroma TRIAS - proved to be efficient, high-throughput alternatives suitable for large-scale clinical testing.

Rack-Hoch et al. (2017)

Comparison of influenza and RSV diagnostic from nasopharyngeal swabs by rapid fluorescent immunoassay (Sofia system) and rapid bedside testing (BinaxNOW) vs. conventional fluorescent immunoassay in a German university children's hospital.

Voermans et al. (2016)

Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and respiratory syncytial viruses.

Beckmann et al. (2015)

Diagnostic performance of near-patient testing for influenza.

Hazelton et al. (2015)

Detection of influenza A and B with the Alere ™ i Influenza A & B: a novel isothermal nucleic acid amplification assay.

Busson et al. (2014)

Evaluation of 3 rapid influenza diagnostic tests during the 2012-2013 epidemic: influences of subtype and viral load.

Clinical performance evaluation of the BD Veritor System Flu A+B assay (Nam et al., 2014)

The BD Veritor™ System offers superior sensitivity compared to traditional assays like BinaxNOW® and SD Influenza Ag, particularly for influenza A, while maintaining 100% specificity. By utilizing a digital reader, it effectively detects lower viral loads that these visual tests often miss. Overall, it provides a faster, more reliable point-of-care solution for early influenza management and infection control.

Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW influenza A&B card for detection of influenza A and B viruses in... (Hassan et al., 2014)

"In summary, the BD Veritor System for Flu A+B was observed to be more sensitive than the Alere BinaxNOW influenza A&B card for detection of influenza A and B viruses from respiratory specimens. In addition, an objective read by the BD Veritor System reader potentially minimizes operator errors, particularly with interpretation of specimens with low viral titers, and this may represent a significant improvement over traditional lateral flow antigen tests used for influenza diagnosis."

Dunn et al. (2014)

Prompt detection of influenza A and B viruses using the BD Veritor™ System Flu A+B, Quidel® Sofia® Influenza A+B FIA, and Alere BinaxNOW® Influenza A&B compared to real-time reverse transcription-polymerase chain reaction (RT-PCR).

Lee et al. (2012)

Evaluation of Sofia fluorescent immunoassay analyzer for influenza A/B virus.

Frequently Asked Questions

Disclaimer: Diagnoodle is intended solely for healthcare professionals and serves as a guide to in-vitro diagnostics (IVD), particularly point-of-care devices. Product availability and approval may vary regionally. Despite careful research, we assume no liability for the completeness, accuracy, or timeliness of the information provided. All liability is excluded.